...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Varenicline augmentation in depressed smokers: an 8-week, open-label study.
【24h】

Varenicline augmentation in depressed smokers: an 8-week, open-label study.

机译：抑郁吸烟者中的缬氨酸增强作用：一项为期8周的开放标签研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To assess possible antidepressant effects of varenicline augmentation in outpatients with treatment-resistant depressive disorders and nicotine dependence. BACKGROUND: Varenicline is a nicotinic acetylcholine receptor alpha4beta2 partial agonist and alpha7 full agonist approved for smoking cessation. Studies of similar compounds have suggested evidence of antidepressant effects. METHOD: Eighteen patients (aged 18 to 65 years) were recruited from a general psychiatric outpatient clinic. Inclusion criteria were (1) primary Axis I depressive disorder (DSM-IV-TR criteria), (2) a stable antidepressant or mood stabilizer regimen, (3) persistent depressive symptoms despite adequate treatment, and (4) current cigarette smoking with nicotine dependence. Patients received varenicline (started at 0.5 mg daily and titrated to 1 mg twice daily) in addition to stable doses of their regular psychotropic medications. Depression symptoms, side effects, clinical global impressions, anhedonia, daily cigarette consumption, and vital signs were assessed every 2 weeks for 8 weeks. Baseline and endpoint ratings were compared, and the relationship between mood improvement and smoking cessation was examined. The primary outcome variable was mean change score in depressive symptoms as assessed by the 16-item Quick Inventory of Depressive Symptomatology-Self-Report. The study was conducted between September 2007 and March 2008. RESULTS: Fourteen patients (78%) completed the study; 4 discontinued due to side effects, including gastrointestinal effects (n = 3) and worsened mood/irritability (n = 1). Patients demonstrated significant improvement in depression at end point (p < .001), with significant improvement as early as week 2. Eight patients (44%) met criteria for categorical response, and 6 (33%) reached remission criteria; the overall effect size was large. All patients were interested in smoking cessation: 8 (44%) achieved abstinence and 9 (50%) had some reduction in smoking. Improvement in depressive symptoms was correlated with smoking cessation. There was no evidence of treatment-emergent suicidality. CONCLUSION: Open-label varenicline augmentation was associated with significant improvement in mood in a small sample of outpatient smokers with persistent depressive symptoms. Larger, double-blind studies are needed to investigate potential antidepressant effects of varenicline augmentation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00525837.
机译：目的：评估伐尼克兰增强对耐治疗性抑郁症和尼古丁依赖的门诊患者的抗抑郁作用。背景：Varenicline是烟碱型乙酰胆碱受体α4beta2部分激动剂和alpha7完全激动剂，被批准用于戒烟。对类似化合物的研究表明有抗抑郁作用的证据。方法：从一般精神科门诊招募18名患者（年龄18至65岁）。入选标准为（1）原发性Axis I抑郁症（DSM-IV-TR标准），（2）稳定的抗抑郁药或情绪稳定剂方案，（3）经过适当治疗后仍持续出现抑郁症状，以及（4）目前吸烟与尼古丁依赖。除了稳定剂量的常规精神药物外，患者还接受了伐尼克兰（起始剂量为每天0.5 mg，每天两次滴定至1 mg）。每隔2周评估抑郁症状，副作用，临床总体印象，性欲减退，每日吸烟和生命体征，共8周。比较基线和终点评分，并检查情绪改善与戒烟之间的关系。主要结果变量是抑郁症状的平均变化评分，该评分由16项抑郁症状自我评估快速清单评估。该研究在2007年9月至2008年3月之间进行。结果：十四名患者（78％）完成了研究。 4例因胃肠道副作用（n = 3）和心情/烦躁不安（n = 1）副作用而停药。患者在终点时表现出抑郁的显着改善（p <.001），最早在第2周就得到了显着改善。8例（44％）达到了分类反应标准，6例（33％）达到了缓解标准。总体效果大小很大。所有患者都对戒烟感兴趣：8（44％）戒烟，9（50％）戒烟。抑郁症状的改善与戒烟有关。没有证据表明治疗有自杀倾向。结论：在少数患有持续性抑郁症状的门诊吸烟者中，开放标签伐尼克兰增强与情绪改善显着相关。需要更大的双盲研究来研究缬尼克酸增强的潜在抗抑郁作用。试验注册：clinicaltrials.gov标识符：NCT00525837。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号